HTX-011 (bupivacaine and meloxicam) for the prevention of postoperative pain – clinical considerations

Author:

Cornett Elyse M1,Turpin Michelle A Carroll2,Busby Matthew3,Pham Alex D4,Kallurkar Anusha5,Brondeel Kimberley C6,Schoonover John7,Arulkumar Sailesh8,Kaye Alan D9

Affiliation:

1. Department of Anesthesiology, Assistant Professor, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA

2. Department of Biomedical Sciences, Assistant Professor of Pharmacology, College of Medicine, University of Houston, Health 2 Building, Room 8037, Houston, TX, USA

3. School of Medicine, LSU Health Shreveport, Shreveport, LA 71103, USA

4. Department of Anesthesiology, LSU Health New Orleans, 1542 Tulane Ave, Room 659, New Orleans, LA 70112, USA

5. Department of Anesthesiology, Resident, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA

6. School of Medicine, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, USA

7. Department of Family Medicine, Resident Physician, St. Anthony Hospital Oklahoma City, 608 NW 9th St Suite 1100, Oklahoma City, OK 73102, USA

8. Department of Interventional Pain, Attending Physician, SSM Hospital, 800 NW 9th St Suite 201, Oklahoma City, OK 73106, USA

9. Provost & Vice Chancellor of Academic Affairs, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA

Abstract

HTX-011 is an extended-release, dual-acting local anesthetic consisting of bupivacaine (sodium-channel blocker) and low-dose meloxicam (non-steroidal anti-inflammatory drug [NSAID]) applied needle-free during surgery. Introducing low-dose meloxicam addresses the limited efficacy of liposomal bupivacaine in acidic inflamed tissues and allows enhanced analgesic effects over three days. It has great promise to be an extremely effective postoperative pain regimen and produce an opioid-free surgical recovery, as it has consistently significantly reduced pain scores and opioid consumption through 72 h. This manuscript provides an updated, concise narrative review of the pharmacology, clinical efficacy, safety and tolerability of this drug and its applications to prevent postoperative pain.

Publisher

Future Medicine Ltd

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3